Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (51-60 of 146) with videos related to

Pageof 15
Sort By:
Journal of the American College of Cardiology|April 25, 2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary interventionDominick J Angiolillo, Joseph A Jakubowski, Francesco Franchi, et al.
Journal of Thrombosis and Thrombolysis|February 14, 2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelorDominick J Angiolillo, Latonya Been, Marc Rubinstein, et al.
Journal of Geriatric Cardiology : JGC|March 22, 2021
Typical atrial flutter from blunt cardiac injury: an atypical causeNaji Maaliki, Fadi Kandah, Aleem Azal Ali, et al.
Journal of Thrombosis and Thrombolysis|September 1, 2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery diseaseMattia Galli, Fabiana Rollini, Latonya Been, et al.
Journal of Cardiology Cases|July 23, 2025
Severe tirofiban-induced thrombocytopenia following percutaneous coronary interventionJohn M Sousou, Kabeer Ali, Melville C O'Brien, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 16, 2024
Switching from cangrelor to oral P2Y<sub>12</sub> inhibitors: a focused review on drug-drug interactionsGiovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, et al.
Expert Review of Clinical Pharmacology|May 17, 2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendationsMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Lancet (London, England)|April 18, 2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisMattia Galli, Stefano Benenati, Davide Capodanno, et al.
International Journal of Cardiology|June 4, 2013
Indexed maximal left atrial volume predicts response to cardiac resynchronization therapyLuca Rossi, Alessandro Malagoli, Massimo Piepoli, et al.
Clinical Pharmacokinetics|April 28, 2023
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of BentracimabLuis Ortega-Paz, Salvatore Giordano, Francesco Franchi, et al.
Pageof 15

Showing results (51-60 of 146) with videos related to

Sort By:
Pageof 15
Journal of the American College of Cardiology|April 25, 2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary interventionDominick J Angiolillo, Joseph A Jakubowski, Francesco Franchi, et al.
Journal of Thrombosis and Thrombolysis|February 14, 2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelorDominick J Angiolillo, Latonya Been, Marc Rubinstein, et al.
Journal of Geriatric Cardiology : JGC|March 22, 2021
Typical atrial flutter from blunt cardiac injury: an atypical causeNaji Maaliki, Fadi Kandah, Aleem Azal Ali, et al.
Journal of Thrombosis and Thrombolysis|September 1, 2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery diseaseMattia Galli, Fabiana Rollini, Latonya Been, et al.
Journal of Cardiology Cases|July 23, 2025
Severe tirofiban-induced thrombocytopenia following percutaneous coronary interventionJohn M Sousou, Kabeer Ali, Melville C O'Brien, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 16, 2024
Switching from cangrelor to oral P2Y<sub>12</sub> inhibitors: a focused review on drug-drug interactionsGiovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, et al.
Expert Review of Clinical Pharmacology|May 17, 2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendationsMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Lancet (London, England)|April 18, 2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisMattia Galli, Stefano Benenati, Davide Capodanno, et al.
International Journal of Cardiology|June 4, 2013
Indexed maximal left atrial volume predicts response to cardiac resynchronization therapyLuca Rossi, Alessandro Malagoli, Massimo Piepoli, et al.
Clinical Pharmacokinetics|April 28, 2023
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of BentracimabLuis Ortega-Paz, Salvatore Giordano, Francesco Franchi, et al.
Pageof 15